UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000000734 |
|---|---|
| Receipt number | R000000882 |
| Scientific Title | Phase II study of FOLFOX4 in patients with advanced/recurrent colorectal cancer previously treated with 5FU (OGSG 0503) |
| Date of disclosure of the study information | 2007/06/15 |
| Last modified on | 2021/11/15 23:02:24 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Phase II study of FOLFOX4 in patients with advanced/recurrent colorectal
cancer previously treated with 5FU (OGSG 0503)
Acronym
OGSG0503
Scientific Title
Phase II study of FOLFOX4 in patients with advanced/recurrent colorectal
cancer previously treated with 5FU (OGSG 0503)
Scientific Title:Acronym
OGSG0503
Region
| Japan |
Condition
Condition
advanced/recurrent colorectal cancer
Classification by specialty
| Gastroenterology | Hematology and clinical oncology | Gastrointestinal surgery |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
A phase II study is designed to evaluate the response and feasibility of FOLFOX4
in patients with advanced/recurrent colorectal cancer previously treated with 5FU
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Pragmatic
Developmental phase
Phase II
Assessment
Primary outcomes
Response Rate
Key secondary outcomes
Incidence of Adverse Events,Feasibility,Survival Time, Relative Dose Intensity
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Historical
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
FOLFOX 4 Treatment
Day 1: 1. L-OHP 85mg/m2 is mixed with 250 cc of 5% glucose infusion.(A)
2. l-LV 100 mg/m2 is mixed with 250 cc of 5% glucose infusion.(B)
3. A and B are drip-infused by 2 hours using Y connection.
4. 5-FU 400mg/m2 is infused by 15 minutes, intravenously
5. 5-FU 600 mg/m2 is infused by 22 hours.
Day 2: 1. l-LV 100mg/m2 is infused by 2 hours.
2. 5-FU 400 mg/m2 is infused by 15 minutes.
3. 5-FU 600 mg/m2 is infused by 22 hours
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 75 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
Eligibility criteria
(1) colorectal cancer, histologically
(2) advanced or recurrent colorectal cancer
(3) colorectal cancers previously treated with 5FU which satisfy the following factors
* more than 4 weeks after the end of prior chemotherapy ( more than two weeks if patients
have progressive lesions)
without previous L-OHP therapy
When patients have been undergone chemotherapy, some signs of progression of tumor
were found in CT or tumor markers within 26 weeks.
(4) with measurable lesions
(5) age: older than 20 years and younger than 75years
(6) Performance Status: 0-2 in ECOG criteria
(7) Longer than 12 weeks of expected survival
(8) sufficient function in the important organs
WBC 4,000<= and =< 12,000 mm3/dl
Platelet 100,000/mm3 <=
Total bilirubin within 1.5 times of normal range of each institute
AST, ALT within 2.5 times of normal range in each institute
Serum creatinin within normal range of each institute
ECG normal range
10) written informed consents
Key exclusion criteria
Excluding Criteria
1. cavity fluid which should be taken out
2. with double cancer and/or multiple cancer which excludes carcinoma in situ
3. with peripheral nerve disorder
4. with infectious disease
5. under the condition of diarrhea (watery diarrhea)
6. with psychological disorder which disturb the entry to the study
7. under continuous steroids therapy
8. with other severe diseases(pulmonary fibrosis, cardiac failure, liver dysfunction, renal dysfunction, intestinal paralysis/obstruction or uncontrolled DM)
9. pregnant and/or nursing women
10. with allergic history against medicines
11. doctors' stop not to register to the study
Target sample size
50
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Mishima Hideyuki |
Organization
National Hospital Organization Osaka National Hospital
Division name
Dpt.Surgery
Zip code
Address
2-1-14,Houenzaka,Chuou-ku,Osaka,540-0006
TEL
06-6942-1331
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Furukawa Hiroshi |
Organization
Sakai City Hospital
Division name
Director
Zip code
Address
1-1-1,Minamiyasuicho,Sakai-ku,Sakai, 590-0064
TEL
072-221-1700
Homepage URL
Sponsor or person
Institute
OGSG
Institute
Department
Personal name
Funding Source
Organization
NPO Osaka Chinical Study Supporting Organization
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2007 | Year | 06 | Month | 15 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2005 | Year | 04 | Month | 21 | Day |
Date of IRB
Anticipated trial start date
| 2005 | Year | 04 | Month | 01 | Day |
Last follow-up date
| 2008 | Year | 01 | Month | 01 | Day |
Date of closure to data entry
| 2008 | Year | 10 | Month | 01 | Day |
Date trial data considered complete
| 2008 | Year | 10 | Month | 01 | Day |
Date analysis concluded
| 2008 | Year | 10 | Month | 01 | Day |
Other
Other related information
Management information
Registered date
| 2007 | Year | 06 | Month | 07 | Day |
Last modified on
| 2021 | Year | 11 | Month | 15 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000882
